Sabby Management’s Arbutus Biopharma ABUS Stock Holding History

Sabby Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,212	Closed	-$2.56K	–	238
2014 Q3	$2.56K	Buy	+1,212	New	+$19.8K	0.1%	90

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Sabby Management's ABUS Position: Q3 2017 in Review

Sabby Management sold out of Arbutus Biopharma (ABUS) in Q3 2017, closing a stake of 248,600 shares — an estimated $895K sold.

Sabby Management first reported a position in ABUS in Q4 2013 and held it in 11 quarters. The position peaked at $4.95M in Q1 2016. 53 funds tracked by Wall St. Rank hold ABUS as of Q3 2017.

Sabby Management reported no remaining Arbutus Biopharma position as of Q3 2017 after selling out during the quarter.
Sabby Management sold 248,600 Arbutus Biopharma shares in Q3 2017, an estimated $895K.
Sabby Management first reported a position in Arbutus Biopharma in Q4 2013 and held it in 11 quarters.
Sabby Management's Arbutus Biopharma position peaked at $4.95M in Q1 2016.
53 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.